FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

washington,	D.C. 20049	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* POON CHRISTINE A					NI	2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [ NBIX ]								neck all appli X Director Officer	ionship of Reportin all applicable) Director Officer (give title		10% Ov Other (s	mer	
(Last) (First) (Middle) 12780 EL CAMINO REAL				3. Date of Earliest Transaction (Month/Day/Year) 05/22/2024									below)	)		below)			
(Ctro at)					4. If Amendment, Date of Original Filed (Month/Day/Year)								Lin	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN DII	EGO CA	<b>A</b> :	92130												filed by Moi		orting Perso n One Repo		
(City)	(State) (Zip)			Rı	Rule 10b5-1(c) Transaction Indication														
									dicate that a tra e defense cond						on or written	plan t	hat is intende	d to	
		Tab	le I - Nor	n-Deriv	ative	Sec	uritie	s Ac	quired, D	ispose	ed c	of, or Be	neficial	ly Owne	t				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				ar) E	2A. Deemed Execution Date, if any (Month/Day/Year		Code (Ins	on Disp	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Benefici Owned	ties Following (I		n: Direct r Indirect sstr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code V	Amo	Amount (A) o		r Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		4. Transa Code (I 8)		of I		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisable	Expirat Date	ion	Title	Amount or Number of Shares						
Restricted Stock Unit <sup>(1)</sup>	\$0	05/22/2024			A		1,435		(2)	(2)		Common Stock	1,435	\$0	1,435		D		
Non- Qualified Stock Option	\$139.43	05/22/2024			A		2,982		(3)	05/22/2	034	Common Stock	2,982	\$0	2,982		D		

## **Explanation of Responses:**

- 1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
- 2. The RSUs will vest in full on May 22, 2025.
- 3. Option vests in 12 monthly installments beginning June 22, 2024.

## Remarks:

/s/ Darin Lippoldt, Attorney-in-05/23/2024

**Fact** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.